OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (37)	5/27/1999 9:04:00 AM
From: scaram(o)uche	Read Replies (1) of 447

biz.yahoo.com UNIONDALE, N.Y., May 27 /PRNewswire/ -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - news) together with its partners Pfizer Inc (NYSE: PFE - news) and New York University, announced today a major expansion of their collaboration in Anaderm Research Corp. The expansion, which will be financed solely by Pfizer, could result in up to $50 million in total payments to OSI over a 6-year period for its R&D activities in the venture. OSI will also receive royalties on sales resulting from successful product development. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next